150 related articles for article (PubMed ID: 36534945)
1. Normalizing the Immune Macroenvironment via Debulking Surgery to Strengthen Tumor Nanovaccine Efficacy and Eliminate Metastasis.
Ma N; Chen Z; Liu G; Yue Y; Li Y; Cheng K; Ma X; Feng Q; Liang J; Zhang T; Gao X; Wang X; Guo X; Zhu F; Nie G; Zhao X
ACS Nano; 2023 Jan; 17(1):437-452. PubMed ID: 36534945
[TBL] [Abstract][Full Text] [Related]
2. Bacterial outer membrane vesicle-based cancer nanovaccines.
Gao X; Feng Q; Wang J; Zhao X
Cancer Biol Med; 2022 Sep; 19(9):1290-300. PubMed ID: 36172794
[TBL] [Abstract][Full Text] [Related]
3. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.
Allen BM; Hiam KJ; Burnett CE; Venida A; DeBarge R; Tenvooren I; Marquez DM; Cho NW; Carmi Y; Spitzer MH
Nat Med; 2020 Jul; 26(7):1125-1134. PubMed ID: 32451499
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
5. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
6. Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8
Qiu L; Valente M; Dolen Y; Jäger E; Beest MT; Zheng L; Figdor CG; Verdoes M
Small; 2018 Apr; 14(15):e1703539. PubMed ID: 29493121
[TBL] [Abstract][Full Text] [Related]
7. Peptide nanovaccine in melanoma immunotherapy.
Dehghankhold M; Sadat Abolmaali S; Nezafat N; Mohammad Tamaddon A
Int Immunopharmacol; 2024 Mar; 129():111543. PubMed ID: 38301413
[TBL] [Abstract][Full Text] [Related]
8. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
[TBL] [Abstract][Full Text] [Related]
10. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery.
Zhao X; Zhao R; Nie G
Nat Protoc; 2022 Oct; 17(10):2240-2274. PubMed ID: 35879454
[TBL] [Abstract][Full Text] [Related]
11. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
12. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.
Zhu G; Mei L; Vishwasrao HD; Jacobson O; Wang Z; Liu Y; Yung BC; Fu X; Jin A; Niu G; Wang Q; Zhang F; Shroff H; Chen X
Nat Commun; 2017 Nov; 8(1):1482. PubMed ID: 29133898
[TBL] [Abstract][Full Text] [Related]
13. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
14. Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment.
Yan WL; Wu CC; Shen KY; Liu SJ
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599024
[TBL] [Abstract][Full Text] [Related]
15. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
16. Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and ultraviolet radiation.
Grabbe S; Bruvers S; Lindgren AM; Hosoi J; Tan KC; Granstein RD
J Leukoc Biol; 1992 Aug; 52(2):209-17. PubMed ID: 1506778
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma inhibits tumor antigen presentation by epidermal antigen-presenting cells.
Grabbe S; Bruvers S; Beissert S; Granstein RD
J Leukoc Biol; 1994 Jun; 55(6):695-701. PubMed ID: 8195694
[TBL] [Abstract][Full Text] [Related]
18. Direct Presentation of Tumor-Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell-Mimicking Nanovaccines.
Zhang J; Fan B; Cao G; Huang W; Jia F; Nie G; Wang H
Adv Mater; 2022 Nov; 34(47):e2205950. PubMed ID: 36217832
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.
Roth MD; Gitlitz BJ; Kiertscher SM; Park AN; Mendenhall M; Moldawer N; Figlin RA
Cancer Res; 2000 Apr; 60(7):1934-41. PubMed ID: 10766183
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
